Leica Biosystems

Leica Biosystems, founded in 1990 and headquartered in Buffalo Grove, USA, is a major player in the diagnostics and medical device sectors, specializing in comprehensive anatomic pathology workflows. The company leverages over 150 years of heritage (through its parent and legacy brands) to offer a fully integrated portfolio including histology instruments, immunohistochemistry (IHC) stainers, digital pathology scanners, and specimen tracking software. As a commercial-stage, revenue-generating entity, it serves laboratories and research institutions worldwide, aiming to standardize and digitize pathology to enhance diagnostic confidence and operational efficiency. It operates as a private company, a subsidiary of Danaher Corporation.

Integrated anatomic pathology workflow platform combining histology instruments (tissue processors, microtomes, stainers), advanced staining systems (IHC/ISH automation), digital pathology scanners & software (Aperio line), and specimen tracking/workflow solutions.

Leica competes with large, diversified diagnostics companies like Roche (Ventana), Agilent, and Sakura, which offer similar histology and staining platforms. In digital pathology, it faces competition from specialized players like Philips and 3DHISTECH, as well as numerous AI software startups. Its integrated workflow approach and Danaher backing are key differentiators.